Payment overview · 2025
General Payments
$567.78
22 reported records · 11 companies
Healthcare provider profile · identity verified
Gerald Wade Mouton, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAKE CHARLES, LA · NPI 1770634628
Verified facts
What the public records show
CMS Open Payments records show Gerald Wade Mouton, MD received $567.78 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.06 | 32.4% | 7 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $116.80 | 20.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.86 | 8.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.38 | 7.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.51 | 7.1% | 2 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $32.62 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.16 | 4.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.52 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.31 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.30 | 3.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.26 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.78 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $112.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.62 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 52 |
| Lisinopril | Lisinopril | 186 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 43 |
| Mounjaro | Tirzepatide | 140 | 19 |
| Alprazolam | Alprazolam | 139 | 20 |
| Ezetimibe | Ezetimibe | 128 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 29 |
| Jardiance | Empagliflozin | 113 | 20 |
| Gabapentin | Gabapentin | 110 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 31 |
| Furosemide | Furosemide | 89 | 25 |
| Metformin Hcl Er | Metformin Hcl | 89 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 17 |
| Tramadol Hcl | Tramadol Hcl | 83 | 23 |
| Ozempic | Semaglutide | 81 | 11 |
| Omeprazole | Omeprazole | 80 | 24 |
| Potassium Chloride | Potassium Chloride | 80 | 21 |
| Valsartan | Valsartan | 72 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 20 |
| Donepezil Hcl | Donepezil Hcl | 67 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 21 |
| Trazodone Hcl | Trazodone Hcl | 61 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 13 |
| Simvastatin | Simvastatin | 59 | 14 |
| Losartan Potassium | Losartan Potassium | 58 | 16 |
| Eliquis | Apixaban | 57 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 16 |
| Allopurinol | Allopurinol | 51 | 14 |
| Memantine Hcl | Memantine Hcl | 48 | 12 |
| Metformin Hcl | Metformin Hcl | 47 | 11 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 11 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 35 | 20 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Kerendia | Finerenone | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 22 |
| Atenolol | Atenolol | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Betamethasone Valerate | Betamethasone Valerate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Repatha Pushtronex | Evolocumab | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.78 · 22 records | ABBVIE INC. | AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, Da Vinci Surgical System, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, LINZESS, MOUNJARO, QULIPTA, SHINGRIX, UBRELVY, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error